Z Squared Inc.
Close on Oct 19, 2026
- Market cap
- $203.02M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Z Squared has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Z Squared filed with the SEC
Z Squared Acquires Energized Arkansas Campus to Advance AI Infrastructure
Material agreement · Acquisition or disposition completed · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Z Squared Inc. Signs Definitive Agreement to Acquire 100% of Paradox
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Z Squared Inc. Terminates At-The-Market Sales
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Z Squared Inc. Appoints Jeffrey Harris
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Z Squared Raises Approximately $15.3 Million in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Russell Indexes Add Z Squared, Inc. to Russell 2000® and Russell
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Squared, Inc. to Acquire Majority Interest in Paradox Data and Its Union County Campus, a Next-Generation Data Center Development Targeting
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 4, 2026.
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Outlines Phase 1 Plan to Reach 100 MW of AI-Ready Infrastructure for Inference Workloads
Regulation FD disclosure · EX-99.1 to Form 8-K
Z Squared to Acquire Skycore Digital, Adding
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Z Squared Announces Executive Leadership Appointments
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CLOSING OF MERGER PRESS RELEASE
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Z Squared Provides Additional Information on
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 24, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Approval of Z Squared Inc.’s Nasdaq Listing Application
Other events · EX-99.1 to Form 8-K
Inc. and Z Squared Inc. Announce Merger Agreement
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Regains Compliance with Nasdaq Listing Rule 5550(a)(2)
Other events · EX-99.1 to Form 8-K
CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATION OF INCORPORATION
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
WEXFORD, PA., Dec. 27, 2024 /PRNewswire/ -- Coeptis
Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from
Other events · EX-99.1 to Form 8-K
Executes Binding Letter of Intent to Acquire
Other events · EX-99.1 to Form 8-K
Granted Continued Listing from Nasdaq Hearings Panel to Regain Compliance with Nasdaq Listing Requirements
Listing notice · Other events · EX-99.1 to Form 8-K
CERTIFICATE OF DESIGNATION OF PREFERENCES,
Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Coeptis Therapeutics Closes on $4.3 Million
Unregistered share sale · Executive or director change · Other events · EX-99.2 to Form 8-K
COEPTIS THERAPEUTICS HOLDINGS, INC. PRESENTATION
Regulation FD disclosure · EX-99.1 to Form 8-K
Coeptis Therapeutics Announces $2 Million Private
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 14, 2023 ANNOUNCING PRICING OF THE UNDERWRITTEN OFFERING
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 16, 2023 ANNOUNCING CLOSING OF THE OFFERING
Material agreement · Other events · EX-99.2 to Form 8-K
Receives Approval to Transfer to The Nasdaq Capital Market
Listing notice · Other events · EX-99.1 to Form 8-K
1 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP C10050 V4.0 18 - May 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Brian Cogley as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Enters into Sponsored Research Agreement with the
Other events · EX-99.1 to Form 8-K
AUDITED FINANCIAL STATEMENTS OF COEPTIS THERAPEUTICS, INC.
Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2021 AND AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2022
Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
COEPTIS THERAPEUTICS HOLDINGS INC. PRESENTATION
Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
1 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics, Inc. Corporate Overview
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 19, 2022
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K